Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04874259 |
TitleLT for Unresectable Colorectal Liver Metastasis | Phase
Not Applicable
|
Date Added 2021-05-05 |
Location
Korea, Republic of
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03400332 |
TitleA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Phase
Phase 1, Phase 2
|
Date Added 2018-01-17 |
Location
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986253, Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03217747 |
TitleAvelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | Phase
Phase 1, Phase 2
|
Date Added 2017-07-14 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Anti-OX40 Antibody PF-04518600, Avelumab, Utomilumab, Bavencio |
Tags
MSS/ MMRp
|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2021-08-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
Tags
MSS/ MMRp
|
| NCT ID NCT03981146 |
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-10 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT04973163 |
TitleA Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Phase
Phase 1
|
Date Added 2021-07-22 |
Location
Texas, United States
Belgium Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BI 1701963, BI 1823911, Midazolam |
Tags
MSS/ MMRp
|
| NCT ID NCT03313778 |
TitleSafety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors | Phase
Phase 1
|
Date Added 2017-10-18 |
Location
District of Columbia, United States
Florida, United States Massachusetts, United States New York, United States Ohio, United States Pennsylvania, United States Australia Japan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
mRNA-4157, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05608044 |
TitleA Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases | Phase
Phase 2
|
Date Added 2022-11-08 |
Location
Arizona, United States
California, United States Colorado, United States Delaware, United States Florida, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Rhode Island, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Belgium Brazil France Georgia Italy Russia Spain |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Balstilimab, Botensilimab, Regorafenib, TAS-102 |
Tags
MSS/ MMRp
|
| NCT ID NCT05609370 |
TitleA Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2022-11-08 |
Location
Alaska, United States
Arizona, United States California, United States Florida, United States Indiana, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nevada, United States New Mexico, United States New York, United States North Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Australia China Puerto Rico |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, capecitabine, LBL-007, Tislelizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
California, United States
Virginia, United States China |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
